CJC-1295/Ipamorelin Stack: Natty or Not? | Still Natty Abstract gradient background for Still Natty peptides guide
Still Natty
Back to Peptides

CJC-1295/Ipamorelin Stack

Natty
growth hormoneGHRHGHSsleepanti-agingselective agonistsubcutaneous

What It Does

Boosts growth hormone 3-5x higher than individual peptides. Improves sleep quality, muscle mass, fat loss, and recovery. Minimal side effects.

Natty Status Classification

This peptide is generally considered within the natty realm by some in the fitness community, particularly when used for therapeutic healing purposes. However, opinions vary, and competitive natural bodybuilding organizations may have different stances. Always check your federation's specific rules if you compete.

Description

Synergistic GHRH + GHRP stack. Dual receptor targeting: sustained + pulsatile GH release. Research shows 3-5x amplification vs monotherapy. CJC-1295: 2-10x GH (6+ days). Ipamorelin: selective, no cortisol spike. Not FDA-approved.

Full Description

CJC-1295/Ipamorelin is a synergistic peptide combination pairing a GHRH analog (CJC-1295) with a selective ghrelin receptor agonist (Ipamorelin) to optimize growth hormone release through complementary mechanisms.

CJC-1295 exists in two forms: WITH DAC (Drug Affinity Complex) featuring 5.8-8.1 day half-life via albumin binding, and WITHOUT DAC (Modified GRF 1-29) with 30-minute to 2-hour half-life.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) highly selective for GHS-R1a without affecting cortisol, prolactin, ACTH, or acetylcholine.

Synergistic mechanism: The peptides target different receptor families in the pituitary gland—CJC-1295 binds GHRH receptors activating G-proteins and increasing cAMP/IP3, while Ipamorelin activates GHS-R1a via phospholipase C generating IP3/DAG and mobilizing intracellular calcium.

This dual-action produces sustained GH elevation (CJC-1295) plus rapid pulsatile spikes (Ipamorelin).

Research on similar GHRH analog + GHRP combinations showed synergistic effects: individual peptides produced 20-fold and 47-fold GH increases respectively, but simultaneous application achieved 54-fold increase.

Clinical practitioners report CJC-1295/Ipamorelin typically produces 3-5 fold greater GH release versus monotherapy, though this specific combination lacks published human trial verification.

Monotherapy data: CJC-1295 WITH DAC produces 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days after single injection; IGF-1 remains elevated 28 days after multiple doses.

Phase 2 trials showed dose-dependent GH/IGF-1 increases at 30-60 mcg/kg with good tolerability but development discontinued after patient death (attributed to unrelated coronary disease).

Ipamorelin showed dose-dependent GH increases and bone growth in preclinical studies but Phase 2 trials for post-operative ileus failed to show efficacy.

The combination may enhance muscle mass, fat metabolism, recovery, and sleep quality through optimized GH pulsatility and sustained elevation.

Critical safety concerns: Cardiovascular risks include increased heart rate, systemic vasodilation, flushing, transient hypotension, potential cardiac hypertrophy, fluid retention, and elevated blood pressure—particularly dangerous with pre-existing heart conditions.

Ipamorelin has minimal side effects (injection site reactions, mild headache, nausea) that typically resolve in 1-2 weeks and does not suppress endogenous hormone production.

Neither peptide is FDA-approved; both classified as Investigational New Drugs for research only.

CJC-1295 removed from FDA Category 2 list September 2024.

Ipamorelin removed from FDA compounding list September 2024 due to nominator withdrawal; FDA recommended against 503A inclusion October 2024 due to insufficient safety data.

Both banned by WADA for competitive sports.

Typical combination dosing: CJC-1295 WITH DAC 1-2mg weekly + Ipamorelin 200-300mcg 1-3x daily; WITHOUT DAC requires daily dosing alongside Ipamorelin.

What is Lyophilized Powder?

Lyophilized powder is a sterile, freeze-dried medication that must be reconstituted (mixed with a liquid solvent, like sterile water) before it can be injected. This process extends the drug's shelf life and stability, making it ideal for temperature-sensitive products. The lyophilization process removes water from the peptide in a frozen state through sublimation, which preserves the physical and chemical properties until it is needed.

Application Methods

  • Subcutaneous injection (both peptides)

Product Names

  • CJC-1295/Ipamorelin Blend
  • CJC-1295 with Ipamorelin
  • Modified GRF 1-29 + Ipamorelin

Benefits

  • 3-5 fold amplification of GH release vs individual peptides (dual receptor synergy)
  • Sustained GH elevation from CJC-1295 + rapid pulsatile spikes from Ipamorelin
  • 2-10 fold GH increase for 6+ days with CJC-1295 WITH DAC component
  • 1.5-3 fold IGF-1 increase sustained 9-11 days, elevated 28 days after multiple doses
  • Highly selective GH release without cortisol or prolactin elevation (Ipamorelin)
  • Improved sleep quality: deeper, more restorative sleep from enhanced GH pulsatility
  • Enhanced body composition: increased muscle mass and improved fat metabolism
  • Accelerated recovery and tissue repair through optimized GH/IGF-1 levels
  • Preserved pulsatile GH secretion patterns vs exogenous GH therapy
  • Minimal side effects compared to other GH secretagogues (no ACTH/acetylcholine effects)
  • Does not suppress endogenous hormone production (Ipamorelin component)
  • Flexible dosing: weekly CJC-1295 WITH DAC + daily Ipamorelin pulses
  • Subcutaneous administration for both peptides
  • Complementary mechanisms optimize natural GH release pathways
  • Enhanced longitudinal bone growth and metabolic improvements in preclinical models

Dosage Levels

  • Beginner Protocol: CJC-1295 WITH DAC 1mg weekly + Ipamorelin 200mcg once daily (bedtime)
  • Standard Protocol: CJC-1295 WITH DAC 1-2mg weekly + Ipamorelin 200-300mcg twice daily (AM + bedtime)
  • Advanced Protocol: CJC-1295 WITH DAC 2mg weekly + Ipamorelin 300mcg three times daily (AM + post-workout + bedtime)
  • Alternative: CJC-1295 WITHOUT DAC 100-200mcg 1-3x daily + Ipamorelin 200-300mcg 1-3x daily (synchronized dosing)
  • Timing: Both on empty stomach, 30-60 min before/after meals
  • Optimal Ipamorelin timing: 2 hours before bedtime for sleep and natural GH alignment
  • CJC-1295 WITH DAC: Inject 1-2x weekly (any time, sustained effect)
  • CJC-1295 WITHOUT DAC: Dose daily or twice daily alongside Ipamorelin
  • Split dosing: Space Ipamorelin 6-8 hours apart to mimic natural GH pulses
  • Cycling: 8-12 weeks on with 5-days-on/2-days-off weekly pattern to prevent desensitization
  • Results timeline: Sleep improvements 2-4 weeks, body composition changes 3-6 months
  • Cardiovascular screening required before use
  • Not recommended for those with pre-existing heart conditions

Research

Where to Buy

*Peptides are stored in form and need to be reconstituted with sterile bacteriostatic water before use.

Related Peptides

Ipamorelin

Natty

Stimulates growth hormone release without cortisol/prolactin effects. Improves sleep quality, recovery, and body composition. Minimal side effects.

CJC-1295

Natty

Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.

MK-677

Natty

Increases lean muscle mass, bone density, and deep sleep quality. Enhances recovery and tissue healing. Risk of blood sugar issues.
Last Updated: 10/23/2025